Back to results

Massachusetts Institute of Technology

The role of mismatch repair and recombination in cellular responses to the DNA damaging anticancer drug Cisplatin

Abstract

dc:description.abstract

Cisplatin (cis-diamminedichloroplatinum(ll)) is a successful DNA-damaging anticancer drug used in the treatment of testicular, ovarian and other tumors. In the past decade, several mutually non-exclusive hypotheses have been presented to explain the cytotoxic and organotropic effects of this compound. In this work we have focused on the opposing effects of mismatch repair and recombination in mediating cisplatin cytotoxicity. Recombination mutants showed strikingly high sensitivity to cisplatin, while mismatch repair mutants showed low sensitivity and resistance to the drug. These results further illustrated that while recombination promotes cellular survival following cisplatin damage, mismatch repair, in contrast, promotes cisplatin toxicity. The mismatch repair protein MutS recognized cisplatin-DNA adducts with 2-fold higher affinity than adducts of oxaliplatin, a cisplatin analog that does not elicit resistance in mismatch repair mutants. MutS recognized the major cisplatin DNA-adduct, the 1,2-d(GpG) intrastrand crosslink, with equal affinity as a G/T mismatch in the same sequence context. Furthermore, MutS inhibited RecA catalyzed strand exchange reaction at the level of joint molecule formation when the substrate was platinated DNA. In the cell, mismatch repair could potentiate cisplatin toxicity by inhibiting the high levels of recombination that are required for cisplatin survival. Microarray analysis of gene expression following cisplatin damage showed that in contrast to wild type and methylation dam mutant, the methylation-mismatch repair double mutant did not show induction of any significant SOS DNA damage response.

Degree

thesis:*
Department dc:contributor.department
Massachusetts Institute of Technology. Dept. of Chemistry.
Grantor dc:publisher
Massachusetts Institute of Technology
Year dc:date.issued
2002

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Zdraveski, Zoran Z. (Zoran Zare), 1969-
Advisor dc:contributor.advisor
  • John M. Essigmann.

Subjects

dc:subject × 1

Rights

dc:rights
Statement dc:rights
  • M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.
Language dc:language.iso
eng

Identifiers

dc:identifier.*
OAI identifier oai:identifier
oai:dspace.mit.edu:1721.1/8363

Chain of custody

source
Harvested from
MIT
Base URL
dspace.mit.edu/oai/request
Last updated
2026-07-22
Source record
OAI-PMH GetRecord
related terms
citation

Zdraveski, Zoran Z. (Zoran Zare), 1969-. The role of mismatch repair and recombination in cellular responses to the DNA damaging anticancer drug Cisplatin. Massachusetts Institute of Technology, 2002. http://hdl.handle.net/1721.1/8363